KLOW Blend (GHK-Cu / BPC-157 / TB-500 / KPV)
Also known as · KLOW 80 · GLOW + KPV
Overview
A 50 mg / 10 mg / 10 mg / 10 mg blend extending the GLOW formulation with KPV — the C-terminal tripeptide of α-MSH — studied for anti-inflammatory contribution to combined dermal and soft-tissue regeneration.
Research profile · for clinicians
Based on research: extends the GLOW formulation with KPV — the anti-inflammatory C-terminal fragment of α-MSH — to add NF-κB attenuation and mast-cell stabilization to the copper-peptide and repair-peptide effects of the base blend.
Mechanism of action
Adds KPV's reported NF-κB-attenuating and mast-cell-stabilizing activity to the copper-peptide + BPC-157 + TB-500 regenerative pathways, broadening the inflammation-modulation profile.
Research record
- [01]KPV anti-inflammatory studies in colitis and dermal models (Brzoska et al.).
- [02]No published clinical trials of the fixed-ratio quadruple blend.
Selected references
α-MSH and its C-terminal tripeptide KPV in inflammation
Endocr. Rev., 2008